A detailed history of Nisa Investment Advisors, LLC transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, Nisa Investment Advisors, LLC holds 143 shares of MDGL stock, worth $29,934. This represents 0.0% of its overall portfolio holdings.

Number of Shares
143
Previous 129 10.85%
Holding current value
$29,934
Previous $34,000 17.65%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 19, 2024

BUY
$193.33 - $291.99 $2,706 - $4,087
14 Added 10.85%
143 $40,000
Q1 2024

May 01, 2024

BUY
$171.37 - $283.23 $2,227 - $3,681
13 Added 11.21%
129 $34,000
Q4 2023

Jan 25, 2024

SELL
$120.4 - $237.13 $10,836 - $21,341
-90 Reduced 43.69%
116 $26,000
Q3 2023

Nov 02, 2023

BUY
$146.04 - $225.78 $13,143 - $20,320
90 Added 77.59%
206 $30,000
Q2 2023

Aug 11, 2023

SELL
$203.88 - $312.0 $24,465 - $37,440
-120 Reduced 50.85%
116 $26,000
Q1 2023

May 02, 2023

BUY
$231.06 - $307.08 $32,348 - $42,991
140 Added 145.83%
236 $57,000
Q3 2022

Nov 07, 2022

SELL
$60.57 - $79.51 $7,086 - $9,302
-117 Reduced 54.93%
96 $7,000
Q2 2022

Aug 03, 2022

SELL
$58.04 - $100.2 $6,674 - $11,523
-115 Reduced 35.06%
213 $15,000
Q1 2022

Apr 29, 2022

SELL
$55.89 - $101.89 $80,872 - $147,434
-1,447 Reduced 81.52%
328 $32,000
Q4 2021

Feb 03, 2022

SELL
$72.34 - $95.09 $77,186 - $101,461
-1,067 Reduced 37.54%
1,775 $102,000
Q3 2021

Oct 18, 2021

SELL
$78.35 - $105.02 $235 - $315
-3 Reduced 0.11%
2,842 $227,000
Q2 2021

Aug 06, 2021

SELL
$97.2 - $137.59 $29,160 - $41,277
-300 Reduced 9.54%
2,845 $277,000
Q4 2020

Jan 25, 2021

BUY
$110.06 - $133.7 $80,123 - $97,333
728 Added 30.12%
3,145 $350,000
Q3 2020

Oct 20, 2020

SELL
$99.78 - $124.21 $185,989 - $231,527
-1,864 Reduced 43.54%
2,417 $287,000
Q2 2020

Jul 27, 2020

BUY
$60.13 - $125.71 $257,416 - $538,164
4,281 New
4,281 $485,000

Others Institutions Holding MDGL

About MADRIGAL PHARMACEUTICALS, INC.


  • Ticker MDGL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 17,103,400
  • Market Cap $3.58B
  • Description
  • Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...
More about MDGL
Track This Portfolio

Track Nisa Investment Advisors, LLC Portfolio

Follow Nisa Investment Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nisa Investment Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nisa Investment Advisors, LLC with notifications on news.